Intrapartum Glycemic Control in GDMA2

Launched by INOVA HEALTH CARE SERVICES · Dec 3, 2022

Keywords

ClinConnect Summary

Gestational diabetes mellitus (GDM) remains a common pregnancy complication, affecting 6-15% of pregnancies worldwide. The incidence of GDM is expected to continue its global upward trend in light of the growing obesity epidemic and delayed childbearing. GDM is associated with adverse short- and long-term maternal and offspring outcomes. Neonatal hypoglycemia, as a result of fetal hyperinsulinemia, occurs in up to 35% of pregnancies complicated by GDM with potential long-term neurodevelopmental sequelae. In that regard, significant emphasis has been placed on the prevention of neonatal hypo...

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women 18 years or older
• • Non-anomalous singleton gestation
• • Gestational diabetes type A2 diagnosed at 24 weeks' gestation or beyond
• • Planned vaginal delivery at term at Inova Fairfax Women's Hospital
• Exclusion Criteria:
• • Women \< 18 years
• • Fetus with major congenital malformations
• • Twin or higher order gestation
• • Pre-existing diabetes mellitus
• • Exposure to antenatal or any systemic steroids 14 days or less prior to delivery
• • Preterm delivery
• • Scheduled cesarean birth
• • Intrapartum cesarean birth prior to 4-5 cm of cervical dilatation

Trial Officials